

Testimony Date: Thursday, March 17, 2022
SB560 Medical Cannabis Regulatory Act
ProPonent
Oral in-person Testimony

Juanita Ramos
(206)250.7238

The creation of **Clinical Cannabis Research & Development Clinical Trial** will be focused on the treatment of qualified conditions. Study will include and is not limited to:

- Evaluation of clinical or behavioral intervention.
- Addiction treatment, opioid displacement.
- PTSD, mental health

Through this research, Kansas has the opportunity to lead and develop medical cannabis products that will require the issuance of a USFDA drug filing for an Investigational New Drug and a Schedule I DEA License. This license would allow us to study the treatment of particular clinical indications or other qualified clinical conditions as outlined in bill. With respect to partnering companies we believe it important to set the criteria as such:

- that owns no more than 20 percent of any cannabis license in any other state
- has not incurred any penalty fine by cannabis regulators in any other state
- best satisfies the following additional criteria: operation as a company registered in Kansas for at least 12 months prior to the effective date of this act; the degree of subject matter expertise of company personnel in each Kansas-licensed area of work, including medical and pharmaceutical research; the degree to which the qualified partnering have access to innovative medicinal delivery modes that do not involve combustion of marijuana and will conduct further research and development regarding such delivery modes; have previously been awarded a hemp license in Kansas; partnering companies have had successful experience in executing prior agreements with one or more Kansas institutions for research related to hemp or medical cannabis; the lowest proposed reliance upon federal, state and local government funding.

Research & Development will focus on three (3) main clinical cannabis deliveries in unit dose form:

- i) inhaled dry powder, pharmaceutical delivery to the lungs by a dry powder inhaler.
- ii) oral capsule, pharmaceutical delivery to release in the intestines for expeditious efficacy
- iii) Oral dry powder, pharmaceutical delivery to release in the intestines

This Research and Development Amendment will lead to this nations first study focused on dosing of the medical cannabis medicine deliveries. Our goals:

- Prove it is safe and effective at treating a particular clinical condition
- Gather patient outcomes from qualified conditions
- Establish a therapeutic effect as a result of taking cannabis
- Advance pharmaceutical technology through instate manufacturing
- Demonstrate beneficial gain through pharmaceutical delivery
- Prove efficacy and bioavailability on improved methods of delivering clinical cannabis
- Prove formulations and technology
- Specifically target preferred delivery
- Creation of one or more Kansas clinical trial programs related to the dosing of clinical cannabis and gathering of data related to that dosing
- Clinical trial programs will be undertaken between qualified Kansas institution of higher education R&D trials and their partnership with qualified companies

- As part of the Research & Development programs allow the Kansas institutions of higher education to cultivate, process, and dispense clinical cannabis through its partnerships with Kansas qualified companies
- Any and all Kansas residents who qualify with clinical conditions shall be able to register **and** be enrolled in the clinical trial program
- All residents who qualify through clinical conditions shall be able to purchase clinical cannabis from qualified Kansas institutions on higher education research and development trials through the qualified companies involved
- All clinical cannabis produced as part of the clinical trial program or programs shall be traced/tracked from in vitro-to-dispensed sale
- Kansas law enforcement shall be able to access all data gathered as part of the clinical trial program or programs
- Clinical Trials will include relationships with schools to assist in meeting the demand for workers skilled in the cannabis industry (attracts more enrollment dollars not just focused on sports)
- Clinical Trial curriculums can be established
- Establishing a portfolio of case studies and projects to demonstrate sector-specific cannabis knowledge
- The Clinical Trial procedures will prove out the therapeutic effects of cannabis
- Kansas can develop a national model where through a Schedule 1 DEA License, products can be exported
- Kansas can provide a platform that has the opportunity to position its institutions of higher learning as research leaders in an emerging industry
- R&D Clinical Trials for Kansas institutes of higher learning and their qualified KS partners can do this under the R&D under the University but may not openly sell to public
- Develop dosage for ranges qualified conditions as outlined in this legislation
- The focused cultivation and extraction of plants for pharmaceutical medicine

Example of documents from other institutes of higher learning can include:

- Compliance, Regulatory, Public Policy, Cultivation, Distribution and Retail
- Cannabis Biology and Medicinal Plant Chemistry
- Cannabis Physiology as well as pharmaceutical implications and practical applications for the plant
- Analytical and Natural Products – both of which prepare students to work in a lab setting or pursue graduate degrees in biology or chemistry
- Cannabis Extraction and Separation Techniques
- Build a knowledge base to analyze marijuana-related compounds and contaminants
- Health Care Medicine
- Marijuana Law and policy
- Cannabis Agriculture, Horticulture, and Business (knowledge)
- Instrumental Analysis in a Laboratory / Build their own Testing Lab, Retail Store or Growing Operations
- Business and Accounting
- Bioanalytical program
- Develop Core Competencies in Natural Product Separation and Analysis, Safe Product Development and Manufacturing and Evaluation of the Therapeutic Potential of Cannabis
- Functional Foods Research, Natural Product Chemistry, Biosynthesis, Microbiology and Formulation Research and Development in the Pharmaceutical and Nutraceutical Industry
- Hydroponics or Social and Ethical Considerations of Business
- Holistic Health or Economic Botany

I have been taught that Creator blessed with Plant Medicine People to use for healing. Unfortunately, many have misused, made false claims, continued to create “medicines” that are not exactly targeting conditions. We have people who are extremely ill that are crossing into neighboring states to receive “medicine” that isn’t exactly regulated from someone who offers what “they think” they should have.

As a new transplant to Kansas, my family and I are committed to bring the very best of what we have learned in this industry to our new community. My experience in 9 other states with legislation has afforded me the “very best knowledge of what works and the worst of what does not work in this emerging industry.”

Thank you for your courage, focus, and contemplation on this SB580.

When appropriate, I stand for questions.